19785-39-8

Basic information

• Product Name: (4-METHYL-1,3-THIAZOL-2-YL)ACETONITRILE
• Synonyms: AKOS BBS-00003091;AKOS B022783;(4-METHYL-1,3-THIAZOL-2-YL)ACETONITRILE;2-(4-METHYL-1,3-THIAZOL-2-YL)ACETONITRILE;ART-CHEM-BB B022783;(4-Methyl-thiazol-2-yl)acetonitrile;2-Thiazoleacetonitrile, 4-Methyl-;2-(4-Methylthiazol-2-yl)acetonitrile
• CAS NO: 19785-39-8
• Molecular Formula: C₆H₆N₂S
• Molecular Weight: 138.19
• Product Categories: Thiazoles, Isothiazoles & Benzothiazoles;Building Blocks;Thiazole
• Mol File: 19785-39-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 82 °C
• Flash Point: 107.2 °C
• Appearance: /
• Density: 1.205 g/cm³
• Vapor Pressure: 0.018mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (4-METHYL-1,3-THIAZOL-2-YL)ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHYL-1,3-THIAZOL-2-YL)ACETONITRILE(19785-39-8)
• EPA Substance Registry System: (4-METHYL-1,3-THIAZOL-2-YL)ACETONITRILE(19785-39-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: S36/37:Wear suitable protective clothing and gloves.
• Hazardous Substances Data: 19785-39-8(Hazardous Substances Data)

Usage

General Description

(4-Methyl-1,3-thiazol-2-yl)acetonitrile, also known by its Chemical Abstracts Service (CAS) number 144331-96-3, is a chemical compound with the molecular formula C6H6N2S. It is a colorless to pale yellow liquid with a molecular weight of 138.19 g/mol. (4-Methyl-1,3-thiazol-2-yl)acetonitrile is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. It is also used as a building block in the production of various compounds due to its reactivity. The chemical poses health hazards when inhaled, ingested, or in contact with skin and eyes, and proper safety precautions should be practiced when handling it. Additionally, it should be stored and handled in accordance with local regulations and best practices for chemical storage and handling.

InChI:InChI=1/C6H6N2S/c1-5-4-9-6(8-5)2-3-7/h4H,2H2,1H3

Upstream product

• 50398-72-6 2-(chloromethyl)-4-methylthiazole 
• 143-33-9 sodium cyanide 
• 7357-70-2 Cyanothioacetamide 
• 78-95-5 chloroacetone 
• 598-31-2 1-bromoacetone 

Downstream Products

• 147642-48-6 3-Amino-2-benzyl-4-(4-methyl-thiazol-2-yl)-7-nitro-2H-isoquinolin-1-one 
• 125103-17-5 2-Amino-1-benzyl-3-(4-methylthiazol-2-yl)pyrrolo<2,3-b>quinoxaline 
• 117840-81-0 methyl (4-methyl-1,3-thiazol-2-yl)acetate 
• 1009099-63-1 C₁₀H₇F₃N₂OS 
• 1009099-64-2 C₁₀H₇ClF₂N₂OS 
• 1009099-62-0 C₁₄H₁₁F₇N₂OS 
• 1009099-65-3 C₁₂H₇F₇N₂OS 
• 1033002-65-1 6-ethyl-9-(4-methylthiazol-2-yl)-4-phenylpyrano[2,3-f]chromen-2,8-dione 
• 1033002-68-4 9-(4-methylthiazol-2-yl)-4-phenyl-6-propylpyrano[2,3-f]chromen-2,8-dione 
• 1033002-62-8 9-(4-methylthiazol-2-yl)-4-phenylpyrano[2,3-f]chromen-2,8-dione 
• 1191081-09-0 9-(4-methyl-1,3-thiazol-2-yl)-3-(4-fluorophenoxy)-4H,8H-pyrano[2,3-f]chromene-4,8-dione 
• 1217344-59-6 C₂₆H₁₉N₅O₃S 
• 1228017-70-6 4-(4-methyl-1,3-thiazol-2-yl)-1-phenyl-1H-1,2,3-triazol-5-amine 

Relevant articles and documents

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Enantioselective Reaction between 2-(Cyanomethyl)azaarenes and N-Boc-amino Sulfones

A series of 2-(cyanomethyl)azaarenes containing benzothiazole or benzoxazole were designed and synthesized for asymmetric α-functionalization with N-Boc-amino sulfones. The Mannich adducts were obtained in high yields with good diastereo- and enantioselectivities. Aryl-substituted amino sulfones were tolerated under the current conditions, and the reaction can be performed on gram scale in good results.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.